

## DAFTAR PUSTAKA

1. Devarajan P. The use of targeted biomarker for chronic kidney disease. *Chronic Kidney Disease*. 2010; 17(6); 469-79.
2. ESRD Patients in 2013: A global perspective diakses dari [http://www.vision-fmc.com/files/ESRD\\_Patients\\_in\\_2013.pdf](http://www.vision-fmc.com/files/ESRD_Patients_in_2013.pdf)
3. Indonesian Renal Registry (IRR). 5<sup>th</sup> Report of Indonesian Renal Registry 2012. Perhimpunan Nefrologi Indonesia (PERNEFRI). 2013
4. Foley RN, Collins AJ. End-stage renal disease in the United States: An update from the United States Renal Data System. *J Am Soc Nephrol*. 2007; 18: 2644 – 48.
5. Fried LF, Katz R, Cushman M, Sarnak M, Shipak MG, Kuller L, Newman AB. Change in cardiovascular risk factors with progression of kidney disease. *Am J Nephrol*. 2009; 29; 334-41
6. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF 23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Elsevier. Ireland Ltd. 2009.
7. Zoccali C, Benedetto FA, Mallamaci F. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. *J Am Soc Nephrol*. 2004; 15; 1029-37
8. Baberato SH, Bucharles SGE, Sousa AM, Costantini CO, Costantini CRF, Filho RP. Prevalence and prognostic impact of diastolic dysfunction in patients with chronic kidney disease on hemodialysis. *Arq Bras Cardiol*. 2010; 94; 4.
9. Otsuka T, Suzuki M, Yoshikawa H, Sugi K. Left ventricular diastolic dysfunction in the early stage of chronic kidney disease. *Jurnal of Cardiology*. 2009; 54; 199-204.
10. Park M, Hsu C, Li Y, Mishra RK, Keane M, Rosas SE, Dries D, Xie D, et al. Associations between kidney function and subclinical cardiac abnormalities in CKD. *J Am Soc. Nephrol*. 2012; 23; 1725-34.
11. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. *Nat Rev Nephrol*. 2014; 10; 268-78.
12. Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla, Xie H, Appleby D et al. Fibroblast Growth Factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. *Kidney int*. 2011; 79; 1370-78.

13. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. *J Bone Miner Res.* 2004; 19; 429–35.
14. Fukumoto S. Phosphate metabolism and vitamin D. *Bonekey Rep.* 2014; 3; 497.
15. Juppner H. Phosphate and FGF-23. *J Kidney International.* 2011; 79 (121); S24-S27.
16. Titan SM, Zatz R, Jorgetti V et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. (Renal week 2009 abstract F-PO1872). *J Am Soc Nephrol.* 2009; 20; 540A.
17. Vanhusen M, Fischer AK, Lehnhardt A et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. *Kidney int.* 2010; 78; 200-6.
18. Arnlov J. Higher fibroblast growth factor 23 increase the risk of all cause and cardiovascular mortality in the community. *Kidney Int.* 2013; 83; 1968-78.
19. Faul C, Amaral AP, Oskovei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, et al. FGF23 induced left ventricular hypertrophy. *J Clin Invest.* 2011; 121(11); 4393-4408.
20. Seifert ME, Fuentes LDL, Ginsberg D, Rothstein M, Dietzen DJ, Cheng SC, Ross W, et al. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. *Am J Nephrol.* 2014; 39; 392-399.
21. Nagueh SF, Chair GK, Appleton CP, Gillebert TC, Marino PN, Oh JK, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. *Journal of The American Society of Echocardiography.* 2009; 22: 107-133.
22. Yan L, Bowman MAH. Chronic sustained inflammation links to left ventricular hypertrophy and aortic valve sclerosis: a new link between S100/RAGE and FGF23. *Inflammation & Cell Signaling.* 2014: 1-7.
23. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. *Atherosclerosis.* 2009.
24. National Kidney Foundation. KDIGO 2012: Clinical Practice Guideline for the Evaluation and Management Chronic Kidney Disease. *Kidney Int Suppl.* 2013; 3; 1-163.

25. Susalit E. Diagnosis dini penyakit ginjal kronik. Eds: Suhardjono, Dharmaizar, Lidya A, dkk. Dalam JNHC 2009. Jakarta. 2009: 9-13.
26. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. *Lancet*. 2010; 375; 1296-309
27. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, et al. Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic review for the U.S. Preventive Services Task Force and for an American College of physicians Clinical Practice Guideline. *Ann Intern Med*. 2012; 156; 570-81.
28. Effective Health Care Program. Chronic Kidney Disease Stages 1-3: Screening, Monitoring, and Treatment, AHRQ Pub. 2012; 11(12); 1-20.
29. Levin A, Hemmelgarn B, Cullerton B, et al. Guidelines for the management of chronic kidney disease. *CMAJ*. 2008; 179; 1154-65.
30. Berinde AM, Gluhovshi G, Enache A, Luta V, Vernic C, Lungu D, Potencz E et al. Assessment of chronic kidney disease based on necroptic microscopical examination in violent death cases. *Rom J Leg Med*. 2009; 3; 205-212.
31. Tahir K. Management of hypertensive nephropathy. *J Biomed Sci and Res*. 2010; 2 (4); 295-301.
32. Sarathy H, Henriquez G, Abramowitz MK, Kramer H, Rosas SE, Johns T, Kumar J, et al. Abdominal obesity, race and chronic kidney disease in young adults: Result from NHANES 1999-2010. *Plot one*. 2016.
33. Tonelli M, Wanner C. Lipid management in chronic kidney disease: Synopsis of the kidney disease. *Ann intern Med*. 2014; 160; 182-189.
34. Kestenbaum B, Drueke TB. Disorders of calcium phosphate, and magnesium metabolism. *Comprehensive Clinical Nephrology*. 2010; 10; 124-141
35. Brewitz C, Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF 23. *Annu Rev Med*. 2010; 61; 91-104.
36. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. *J Am Soc Nephrol*. 2005; 16; 2205-15.
37. Komaba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. *Nefrologia*. 2009; 29; 392-6.
38. Liu S, Quarles LD. How Fibroblast Growth Factor 23 Works. *J Am Soc Nephrol* 18. 2007; 18; 1637-47.

39. Martin A, David V, Quarles LD. Regulation and function of the FGF23/KLOTHO endocrine pathways. *Physiol Rev.* 2012; 92; 131–55.
40. Leaf DE, Pereire RC, Bazari H, Juppner H. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. *J Clin Endocrinol Metab.* 2013; 98(3); 887-891
41. Saito T, Fukutomo S. Fibroblast growth factor 23 (FGF23) and disorders of phosphate metabolism. *Int J of Pediatric endocrinology.* 2009: 1-6
42. Brownstein CA, Zhang J, Stillman A et al. Increased bone volume and correlation of HYP mouse. *Endocrinology.* 2010: 151; 492-501.
43. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, et al. Sensitivity of fibroblast growth factor 23: Measurements in tumor-induced osteomalacia. *J.Clin. Endocrinol Metab.* 2006: 91(6); 2055-2061.
44. Hu P, Xuan Q, Hu B, Lu L, Wang J, Qin YH. Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease. *International Journal of Biological Sciences.* 2012: 8(5); 663-71.
45. Juppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling? *J Bone Miner Res.* 2010: 25; 2091-7.
46. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *European Heart Journal.* 2011: 32; 2999-3054.
47. Gutierrez OM, Januzzi JL, Iskanova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation.* 2009: 119; 2545-52.
48. Shimada T, Urakawa I, Isakova T, et al. Circulating fibroblast growth factor 23 in patient with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. *J Clin Endocrinol Metab.* 2010: 95; 578-85.
49. Westerberg PA, Linde T, Wikstrom B, et al. Regulation of fibroblast growth factor-23 in chronic kidney disease. *Nephrol Dial Transplant.* 2007: 22; 3202-7.
50. Perwad F, Azam N, Zhang MY, et al. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. *Endocrinology.* 2005: 146; 5358-64.

51. Ito M, Sakai Y, Furumoto M, et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. *Am J Physiol Endocrinol Metab.* 2005; 288; E1101-9.
52. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. *N Engl J Med.* 2008; 359; 584-92.
53. Tortora GJ, Derrickson B. *Principles of anatomy and physiology.* 11th edition, USA. 2006.
54. Sanderson JE, Yu TT. Heart Failure with a Normal Ejection Fraction. In *Heart Failure in Clinical Practice.* Springer, London, 2010; 6; 122-38
55. Kapila R, Mahajan RP. Diastolic dysfunction. *Continuing Education in Anaesthesia, Critical Care and Pain* 2009 ; 9 : 29-33.
56. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R et al. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and preserved ejection fraction. *Circulation.* 2011; 124; 2491-501.
57. Appleton CP, Kovacs SJ. The role of left atrial function in diastolic heart failure. *Circ Cardiovasc Imaging* 2009 ; 2 : 6-9.
58. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. *Circulation.* 2013; 128(4); 388-400.
59. Redfield MM. Recognizing and managing the patient with heart failure and preserved ejection fraction. In *Management of Heart Failure.* Wiley-Blackwell, UK. 2011.
60. Falcao PI, Hamdani N, Barbely A, Gavino C, Schalkwijk CG, Vander VJ, Van HL, et al. Diabetes worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. *Circulation.* 2011; 124; 1151-59.
61. Erwinanto, Putranto JNE, Tedjasukmana P, Suryawan R, Rifqi S, Kasiman S. *Pedoman Tatalaksana dislipidemia.* Perhimpunan dokter spesialis kardiovaskular indonesia. 2013.
62. Son JI, Chin SO, Taek J. Treatment guidelines for dyslipidemia: Summary of the expanded second version. *The Korean society lipidology and atherosclerosis. J lipid of atheroscler.* 2012; 1(2); 45-59.

63. Klein AL, Craigh RA. Pericardium, Restrictive Cardiomyopathy and Diastolic Dysfunction. Textbook of cardiovascular medicine, 3rd edition. Lippincott Williams & Wilkins, Philadelphia. 2007. 420-59.
64. Satpathy C, Mishra TK, Satpathy R, et al. Diagnosis and management of diastolic dysfunction and heart failure. *Am Fam Physician* 2006;73:841-6.
65. McMurray J, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *European Heart Journal*. 2012: 33; 1787–1847.
66. Takatsuji H, Mikami T, Urasawa K. A New approach for evaluation of left ventricular Mottram P, Marwick TH. Assessment of diastolic function: what the general cardiologist needs to know. *Heart*. 2005; 91; 681-95.
67. Carsten T, Mario K, Dirk W, Regina G, Wolfgang C. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. *European Heart Journal*. 2005; 26: 2277-2284.
68. Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, Xuan W, et al. FGF23 Promotes myocardial fibrosis in mice through activation of  $\beta$ -catenin. *Oncotarget journal*. 2016: 7(40); 64649-64664.
69. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study. *J Am Society of Nephrol*. 2007: 18; 2601-2608.
70. Chathoth S, Mueio SA, Cyrus C, Vatte C, Nafaie AA, Ali RA, Keating BJ, et al. Elevated fibroblast growth factor 23 concentration: prediction of mortality among chronic kidney disease patients. *Cardiorenal Med*. 2016: 6; 73-82.
71. Tjekyan RMS. Prevalensi dan faktor risiko penyakit ginjal kronik di RSUP dr. Mohammad Hoesin Palembang tahun 2012. *MKS*. Th 46. 2014: 4; 276-282.
72. Krol GD. Chronic kidney disease-Clinical practice recommendation for primary care physicians and health care providers. *Henry ford health system*. 2011: 7; 4-10.
73. Sakan H, Nakatani K, Asai O, Imura A, Tanaka T, Yoshimoto S, Iwamoto N, et al. Reduced renal  $\alpha$ -klotho expression in CKD patients and its effect on renal phosphate handling and vitamin D metabolism. *Plos One*. 2014: 9; 1.

74. Negishi K, Kobayashi M, Ochiai I, Yamazaki Y, Hasegawa H, Yamashita T, Shimizu T, et al. Association between fibroblast growth factor 23 and left ventricular hypertrophy in maintenance hemodialysis patients. *Circulation journal*. 2010; 74; 2734-2740.
75. Okamoto Y, Fijita S, Morita H, Kizawa S, Ito T, Sakane K, Sohmiya K, et al. Association between circulating FGF23,  $\alpha$ -Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction. *Springer Heart Vessels*. 2016; 31; 66-73.

